The cells survival is important when it comes to measuring the toxic effects of chemical compounds, especially in case of a cancer drug in which along with the cancer cells most of the healthy cells are also lost. Cell survival is also important in case of industrial and agricultural chemical as well as other environmental regulations so as to study the dreadful effects on the healthy cells. The MIT biological engineers have developed a novel toxicity test for chemicals effect measurement in case of cell survival with higher sensitivity in comparison to the presently used tests.
The popular gold-standard test takes weeks for yielding results but in case of the new test, the evaluation and identification of the drugs is quicker, which is profitable for the drug companies and academic researchers. According to Le Ngo, a former MIT graduate student, along with his other colleagues believed the traditional tests like cytotoxicity assays, colony formation assay, and others grew cells in wells before testing chemical compounds or radiations followed by the counting method. In substitution to the manual counting, the mitochondrial function analysis helps ease the method but in terms of accuracy and sensitivity, it is a step behind. The new technique named MicroColonyChip could generate results within a few days. The wells’ separation for control and toxicity test along with the fluorescently labels for DNA imaging has made the cell survival measurement simpler.
The use of a software program in the new method can make the calculation less manual and more computational for low chances of error. The automatic scanning system helped obtain indistinguishable results. The new test even stood up to the commonly used XTT and CellTiter-Glo (CTG) toxicity tests used by researchers and pharmaceutical companies. The environmental regulations, drug developments, and personalized medicine can use the tests for toxic compounds impact on healthy cells. The Infectious Diseases Society of America’s 10 x ’20 initiative is waiting to see if 10 of the new systemic antibacterial drugs will be approved by 2020 by the FDA. The antibacterial drug development has dipped down owing to the multidrug resistance, cell toxicity issues, and lack of new target research.